Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Precision BioSciences (DTIL) Misses Q2 EPS by 4c, Revenues Miss
August 13, 2020 7:06 AM EDTPrecision BioSciences (NASDAQ: DTIL) reported Q2 EPS of ($0.63), $0.04 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $1.08 million versus the consensus estimate of $4.39 million.
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple MyelomaPBCAR0191 and PBCAR20A Clinical Studies Progressing; Updated Interim Data... More